# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus

> **NCT02445911** · PHASE1 · COMPLETED · sponsor: **Kaneq Bioscience Limited** · enrollment: 81 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** KQ-791
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02445911
- **Lead sponsor:** Kaneq Bioscience Limited
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2019-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02445911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02445911, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02445911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*